Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of Basilea Pharmaceutica patents

Patents where

Current Assignee

Name

Basilea Pharmaceutica

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 7385061 Furazanobenzimidazoles	Patent 7385061 was granted and assigned to Basilea Pharmaceutica on June, 2008 by the United States Patent and Trademark Office.		Basilea Pharmaceutica	United States Patent and Trademark Office	7385061	June 10, 2008
‌ US Patent 11633383 Dosage principle for drugs useful for treating neoplastic diseases	Patent 11633383 was granted and assigned to Basilea Pharmaceutica on April, 2023 by the United States Patent and Trademark Office.	Basilea Pharmaceutica	Basilea Pharmaceutica	United States Patent and Trademark Office	11633383	April 25, 2023
‌ US Patent 7115643 Intermediate halophenyl derivatives and their use in a process for preparing azole derivatives	Patent 7115643 was granted and assigned to Basilea Pharmaceutica on October, 2006 by the United States Patent and Trademark Office.		Basilea Pharmaceutica	United States Patent and Trademark Office	7115643	October 3, 2006
‌ US Patent 7531650 Cephalosporin salts in crystalline form	Patent 7531650 was granted and assigned to Basilea Pharmaceutica on May, 2009 by the United States Patent and Trademark Office.		Basilea Pharmaceutica	United States Patent and Trademark Office	7531650	May 12, 2009
‌ US Patent 7262307 1′-benzyl-3-bromo-[1,3′]bipyrrolidinyl-2-one	Patent 7262307 was granted and assigned to Basilea Pharmaceutica on August, 2007 by the United States Patent and Trademark Office.		Basilea Pharmaceutica	United States Patent and Trademark Office	7262307	August 28, 2007
‌ US Patent 7151182 Intermediates for N-substituted carbamoyloxyalkyl-azolium derivatives	Patent 7151182 was granted and assigned to Basilea Pharmaceutica on December, 2006 by the United States Patent and Trademark Office.		Basilea Pharmaceutica	United States Patent and Trademark Office	7151182	December 19, 2006
‌ US Patent 7459561 N-substituted carbamoyloxyalkyl-azolium derivatives	Patent 7459561 was granted and assigned to Basilea Pharmaceutica on December, 2008 by the United States Patent and Trademark Office.		Basilea Pharmaceutica	United States Patent and Trademark Office	7459561	December 2, 2008
‌ US Patent 8486996 Aroylfuranes and aroylthiophenes	Patent 8486996 was granted and assigned to Basilea Pharmaceutica on July, 2013 by the United States Patent and Trademark Office.		Basilea Pharmaceutica	United States Patent and Trademark Office	8486996	July 16, 2013
‌ US Patent 9970938 Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles	Patent 9970938 was granted and assigned to Basilea Pharmaceutica on May, 2018 by the United States Patent and Trademark Office.	Basilea Pharmaceutica	Basilea Pharmaceutica	United States Patent and Trademark Office	9970938	May 15, 2018
‌ US Patent 7524823 Macrolides	Patent 7524823 was granted and assigned to Basilea Pharmaceutica on April, 2009 by the United States Patent and Trademark Office.		Basilea Pharmaceutica	United States Patent and Trademark Office	7524823	April 28, 2009
‌ US Patent 7951957 Substituted benzimidazoles and their use for inducing apoptosis	Patent 7951957 was granted and assigned to Basilea Pharmaceutica on May, 2011 by the United States Patent and Trademark Office.		Basilea Pharmaceutica	United States Patent and Trademark Office	7951957	May 31, 2011
‌ US Patent 8927541 Tricyclic antibiotics	Patent 8927541 was granted and assigned to Basilea Pharmaceutica on January, 2015 by the United States Patent and Trademark Office.		Basilea Pharmaceutica	United States Patent and Trademark Office	8927541	January 6, 2015
‌ US Patent RE42890 Furazanobenzimidazoles	Patent RE42890 was granted and assigned to Basilea Pharmaceutica on November, 2011 by the United States Patent and Trademark Office.		Basilea Pharmaceutica	United States Patent and Trademark Office	RE42890	November 1, 2011
‌ US Patent 9321788 Tricyclic antibiotics	Patent 9321788 was granted and assigned to Basilea Pharmaceutica on April, 2016 by the United States Patent and Trademark Office.		Basilea Pharmaceutica	United States Patent and Trademark Office	9321788	April 26, 2016
‌ US Patent 7423157 Substituted benzimidazoles and their use for inducing apoptosis	Patent 7423157 was granted and assigned to Basilea Pharmaceutica on September, 2008 by the United States Patent and Trademark Office.		Basilea Pharmaceutica	United States Patent and Trademark Office	7423157	September 9, 2008
‌ US Patent 10590092 Process for the manufacture of isavuconazole or ravuconazole	Patent 10590092 was granted and assigned to Basilea Pharmaceutica on March, 2020 by the United States Patent and Trademark Office.	Basilea Pharmaceutica	Basilea Pharmaceutica	United States Patent and Trademark Office	10590092	March 17, 2020
‌ US Patent 8716280 Bicyclic antibiotics	Patent 8716280 was granted and assigned to Basilea Pharmaceutica on May, 2014 by the United States Patent and Trademark Office.		Basilea Pharmaceutica	United States Patent and Trademark Office	8716280	May 6, 2014
‌ US Patent 10487075 Substituted mono- and polyazanaphthalene derivatives and their use	Patent 10487075 was granted and assigned to Basilea Pharmaceutica on November, 2019 by the United States Patent and Trademark Office.	Basilea Pharmaceutica	Basilea Pharmaceutica	United States Patent and Trademark Office	10487075	November 26, 2019
‌ US Patent 8933073 Macrolides and their use	Patent 8933073 was granted and assigned to Basilea Pharmaceutica on January, 2015 by the United States Patent and Trademark Office.	Basilea Pharmaceutica	Basilea Pharmaceutica	United States Patent and Trademark Office	8933073	January 13, 2015
‌ US Patent 8173609 Macrolides useful against inflammatory and allergic diseases	Patent 8173609 was granted and assigned to Basilea Pharmaceutica on May, 2012 by the United States Patent and Trademark Office.		Basilea Pharmaceutica	United States Patent and Trademark Office	8173609	May 8, 2012
‌ US Patent 8445451 Macrolides and uses of macrolides	Patent 8445451 was granted and assigned to Basilea Pharmaceutica on May, 2013 by the United States Patent and Trademark Office.		Basilea Pharmaceutica	United States Patent and Trademark Office	8445451	May 21, 2013
‌ US Patent 8802858 Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases	Patent 8802858 was granted and assigned to Basilea Pharmaceutica on August, 2014 by the United States Patent and Trademark Office.		Basilea Pharmaceutica	United States Patent and Trademark Office	8802858	August 12, 2014
‌ US Patent 9366682 Use of stathmin as a biomarker of drug response to furazanobenzimidazoles	Patent 9366682 was granted and assigned to Basilea Pharmaceutica on June, 2016 by the United States Patent and Trademark Office.		Basilea Pharmaceutica	United States Patent and Trademark Office	9366682	June 14, 2016
‌ US Patent 10724072 Use of phospho-Akt as a biomarker of drug response		Basilea Pharmaceutica	Basilea Pharmaceutica	United States Patent and Trademark Office	10724072	July 28, 2020
‌ US Patent 9499566 Oxidation process for preparing 3-formyl-cephem derivatives	Patent 9499566 was granted and assigned to Basilea Pharmaceutica on November, 2016 by the United States Patent and Trademark Office.	Basilea Pharmaceutica	Basilea Pharmaceutica	United States Patent and Trademark Office	9499566	November 22, 2016

Results per page:

57 results

0 selected

57 results

0 selected